Crispr Therapeutics [CRSP] vs Regeneron [REGN] Detailed Stock Comparison

Crispr Therapeutics AG

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Crispr Therapeutics AG wins in 2 metrics, Regeneron Pharmaceuticals, Inc. wins in 16 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Crispr Therapeutics AG Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) -8.52 18.00 Regeneron Pharmaceuticals, Inc.
Price-to-Book Ratio 2.77 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 10.76 9.51 Regeneron Pharmaceuticals, Inc.
PEG Ratio -0.04 -4.80 Crispr Therapeutics AG
EV/EBITDA -6.49 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) 0.00% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) -17,912.50% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) N/A 23.13% N/A
Return on Equity -30.18% 14.86% Regeneron Pharmaceuticals, Inc.
Return on Assets (TTM) -15.76% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-370.93M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 54.81% 25.39% Crispr Therapeutics AG
Price-to-Sales Ratio (TTM) 1,518.81 5.50 Regeneron Pharmaceuticals, Inc.
Enterprise Value $3.56B $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio 1,014.80 4.95 Regeneron Pharmaceuticals, Inc.
Gross Profit Margin (TTM) N/A 84.95% N/A
Revenue per Share (TTM) $0 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $-6.47 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 1.79 0.40 Regeneron Pharmaceuticals, Inc.
Short % of Float 26.43% 2.55% Regeneron Pharmaceuticals, Inc.

Crispr Therapeutics AG vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

CRSP
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Crispr Therapeutics AG0.15%-2.67%-2.76%-10.27%-6.95%-3.11%
Regeneron Pharmaceuticals, Inc.2.66%-1.40%-12.73%-19.27%-14.47%-20.27%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Crispr Therapeutics AG54.81%-13.57%-50.41%306.51%306.51%306.51%
Regeneron Pharmaceuticals, Inc.25.39%-16.92%20.10%53.41%959.24%4,557.42%

Performance & Financial Health Analysis: Crispr Therapeutics AG vs Regeneron Pharmaceuticals, Inc.

MetricCRSPREGN
Market Information
Market Cap i$5.30B$80.98B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i1,664,933642,495
90 Day Avg. Volume i2,131,141617,765
Last Close$52.10$618.95
52 Week Range$36.08 - $78.48$476.49 - $821.11
% from 52W High-33.61%-24.62%
All-Time High$220.20 (Jan 11, 2021)$1,211.20 (Aug 26, 2024)
% from All-Time High-76.34%-48.90%
Growth Metrics
Quarterly Revenue Growth-0.98%0.03%
Quarterly Earnings Growth-1.00%-0.08%
Financial Health
Profit Margin (TTM) i0.00%0.31%
Operating Margin (TTM) i-179.13%0.23%
Return on Equity (TTM) i-0.30%0.15%
Debt to Equity (MRQ) i10.769.51
Cash & Liquidity
Book Value per Share (MRQ)$20.04$304.65
Cash per Share (MRQ)$20.59$83.86
Operating Cash Flow (TTM) i$-345,014,016$4.98B
Levered Free Cash Flow (TTM) i$-205,623,744$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Crispr Therapeutics AG vs Regeneron Pharmaceuticals, Inc.

MetricCRSP (Apr 24, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-8.5218.00
Forward P/E i-13.2614.21
PEG Ratio i-0.04-4.80
Price to Sales (TTM) i1,518.815.50
Price to Book (MRQ) i2.772.45
Market Capitalization
Market Capitalization i$5.30B$80.98B
Enterprise Value i$3.56B$70.98B
Enterprise Value Metrics
Enterprise to Revenue i1,014.804.95
Enterprise to EBITDA i-6.4916.72
Risk & Other Metrics
Beta i1.790.40
Book Value per Share (MRQ) i$20.04$304.65

Financial Statements Comparison: Crispr Therapeutics AG vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCRSP (2025)REGN (2025)
Revenue/Sales i014.34B
Cost of Goods Sold i213.48M2.10B
COGS % of Revenue i-14.6%
Gross Profit i-213.48M12.24B
Gross Margin i-85.4%
Research & Development i381.06M5.85B
Operating Income (EBIT) i-664.57M3.70B
Operating Margin i-25.8%
EBITDA i-645.09M5.00B
EBITDA Margin i-34.8%
Pre-Tax Income i-577.97M5.23B
Pre-Tax Income % of Revenue i-36.5%
Income Tax i3.63M725.80M
Income Tax % of Revenue i-5.1%
Net Income (Profit) i-581.60M4.50B
Profit Margin i-31.4%

Balance Sheet & Liquidity Metrics

MetricCRSP (2025)REGN (2025)
Cash & Equivalents i347.56M3.12B
Total Current Assets i1.99B18.02B
Total Current Assets % of Revenue i-125.7%
Total Current Liabilities i149.12M4.37B
Total Current Liabilities % of Revenue i-30.5%
Long-Term Debt i188.17M2.71B
Long-Term Debt % of Revenue i-18.9%
Total Shareholders Equity i1.92B31.26B
Retained Earnings i-1.95B35.80B
Retained Earnings % of Revenue i-249.6%
Property, Plant & Equipment i175.30M1.54B

Cash Flow Statement Comparison

MetricCRSP (2025)REGN (2025)
Operating Cash Flow i-393.25M6.30B
Operating Cash Flow % of Revenue i-43.9%
Capital Expenditures i-914,0000
Free Cash Flow i-370.93M3.77B
FCF Margin i-26.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/A-3.97B

Short Interest & Institutional Ownership Analysis

MetricCRSPREGN
Shares Short i22.62M2.55M
Short Ratio i10.014.46
Short % of Float i26.43%2.55%
Shares Outstanding i95.89M105.72M
Float Shares i95.55M98.55M
% Held by Insiders i4.88%1.98%
% Held by Institutions i73.33%91.08%
% Held by Public i21.79%6.94%

Dividend Analysis & Yield Comparison: Crispr Therapeutics AG vs Regeneron Pharmaceuticals, Inc.

MetricCRSPREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026